Synopsis:
This Pharmaceutical stock is in the news today following the announcement of a strong Q2 result with 73 percent growth in profits and 24 percent growth in its revenue along with Strong performance in the US market.
The shares of this company which is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions were in news today as company declared its Q2 results with strong performance metrics and growth in international business.
With a market cap of Rs 89,842 crore, the shares of Lupin Ltd gained about 2.33 percent percent reaching a high of Rs 2001.75 when compared to its previous day closing price of Rs 1956.05 .The shares are trading at 17 percent discount from its 52 week high of Rs 2,403.45 and have given a return of 177 percent over the last 3 years.
Q2 FY26 Result highlights
The Revenue from operations for the company stood at Rs 6,831.43 crore when compared to Rs 5,497.01 crore in Q2 FY25, growing by about 24 percent YoY and on QoQ increasing by 11 percent from Rs 6,163.75 crore in Q1 FY26.
The profit after tax grew by about 73 percent YoY when you compare the Q2 FY26 at Rs 1,484.83 crore to Rs 859.48 crore in Q2 FY25, and on QoQ basis has increased 21.56 percent from Rs 1,221.45 crore in Q1 FY26.
The EBITDA margin is at 35.6 percent compared to 25.2 percent in Q2 FY25 and EBITDA is at Rs 2,431.3 crores compared to Q2 FY25 EBITDA which is at Rs 1,382.7 crores with 76 percent YoY growth.
During the quarter, the company continued its strong focus on innovation, investing Rs 509.1 crore in research and development , accounting for 7.5 percent of its total sales. As of September 30, 2025, the company’s operating working capital stood at Rs 7,730.4 crore, reflecting efficient management of its operational resources. Capital expenditure for the quarter came in at Rs 347.4 crore, underscoring ongoing investments in capacity and modernization. Notably, the company maintained a net debt position of Rs -1,664.6 crore, indicating a healthy net cash balance, with a net debt-to-equity ratio of -0.08, highlighting its robust financial strength and low leverage.
Lupin’s U.S. sales for Q2 FY26 stood at Rs 2,762 crore, a strong 47.3 percent YoY growth from Rs 1,875 crore in Q2 FY25. In dollar terms, revenue rose to USD 315 million from USD 223 million, contributing 40 percent of the company’s global sales. During the quarter, Lupin secured 6 ANDA approvals from the U.S. FDA and launched 6 new products, expanding its U.S. portfolio to 147 generic drugs. The company retained its position as the 3rd largest player in both the U.S. generic and total prescription markets (IQVIA, Q3 2025), leading in 49 products and ranking among the top three in 113 of its marketed generics.
Mr. Nilesh Gupta, Managing Director, Lupin Limited said “We are delighted to present one of our strongest performances ever in this second quarter of FY26. We continue to see robust growth in revenues and EBITDA led by strong performance across the board, in the U.S., emerging markets, other developed markets and in India, supported by higher operational efficiencies and sustained investments. We intend to leverage the performance of H1 to deliver a strong FY26”.
About the company
Lupin Limited, headquartered in Mumbai, is a global pharmaceutical company with a presence in over 100 markets worldwide. The company develops and manufactures a wide range of branded and generic medicines, complex generics, biotech products, and active pharmaceutical ingredients (APIs).
With a strong foothold in India and the U.S., Lupin serves key therapeutic areas such as respiratory, cardiovascular, diabetes, infectious diseases, gastrointestinal, CNS, and women’s health. Backed by 15 manufacturing sites, 7 R&D centers, and a 24,000-strong workforce, Lupin continues to drive innovation and improve patient outcomes through its subsidiaries, which are Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Written by Leon Mendonca.
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
